

Accepted Manuscript

Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models



Ryan M. Esquejo, Christopher T. Salatto, Jake Delmore, Bina Albuquerque, Allan Reyes, Yuji Shi, Rob Moccia, Emily Cokorinos, Matthew Peloquin, Mara Monetti, Jason Barricklow, Eliza Bollinger, Brennan K. Smith, Emily A. Day, Chuong Nguyen, Kieran F. Geoghegan, John M. Kreeger, Alan Opsahl, Jessica Ward, Amit S. Kalgutkar, David Tess, Lynne Butler, Norimitsu Shirai, Timothy F. Osborne, Gregory R. Steinberg, Morris J. Birnbaum, Kimberly O. Cameron, Russell A. Miller

PII: S2352-3964(18)30137-3
DOI: [doi:10.1016/j.ebiom.2018.04.009](https://doi.org/10.1016/j.ebiom.2018.04.009)
Reference: EBIOM 1423
To appear in: *EBioMedicine*
Received date: 8 December 2017
Revised date: 26 March 2018
Accepted date: 6 April 2018

Please cite this article as: Ryan M. Esquejo, Christopher T. Salatto, Jake Delmore, Bina Albuquerque, Allan Reyes, Yuji Shi, Rob Moccia, Emily Cokorinos, Matthew Peloquin, Mara Monetti, Jason Barricklow, Eliza Bollinger, Brennan K. Smith, Emily A. Day, Chuong Nguyen, Kieran F. Geoghegan, John M. Kreeger, Alan Opsahl, Jessica Ward, Amit S. Kalgutkar, David Tess, Lynne Butler, Norimitsu Shirai, Timothy F. Osborne, Gregory R. Steinberg, Morris J. Birnbaum, Kimberly O. Cameron, Russell A. Miller , Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. *Ebiom*(2017), doi:[10.1016/j.ebiom.2018.04.009](https://doi.org/10.1016/j.ebiom.2018.04.009)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models

Ryan M. Esquejo¹, Christopher T. Salatto¹, Jake Delmore¹, Bina Albuquerque¹, Allan Reyes¹, Yuji Shi¹, Rob Moccia², Emily Cokorinos¹, Matthew Peloquin¹, Mara Monetti¹, Jason Barricklow³, Eliza Bollinger¹, Brennan K. Smith⁴, Emily A. Day⁴, Chuong Nguyen⁵, Kieran F. Geoghegan⁵, John M. Kreeger⁶, Alan Opsahl⁶, Jessica Ward¹, Amit S. Kalgutkar⁷, David Tess⁷, Lynne Butler⁶, Norimitsu Shirai⁶, Timothy F. Osborne⁷, Gregory R. Steinberg⁴, Morris J. Birnbaum¹, Kimberly O. Cameron⁸, Russell A. Miller^{1*}

¹ Internal Medicine Research Unit, Pfizer Inc, Cambridge, MA, USA

² Computational Sciences, Pfizer Inc, Cambridge MA

³ Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc, Groton CT

⁴ Division of Endocrinology and Metabolism, Department of Medicine and Department of Biochemistry and Biomedical Sciences, McMaster University, 1280 Main St. W., Hamilton, Ontario L8N 3Z5, Canada

⁵ Primary Pharmacology Group, Pfizer Inc, Groton CT

⁶ Drug Safety Research and Development, Pfizer Inc, Groton CT

⁷ Sanford Burnham Prebys Medical Discovery Institute, 6400 Sanger Road, Orlando, FL 32827, USA

⁸ Medicine Design, Pfizer Inc, Cambridge MA

* Corresponding and lead contact author

Address correspondence to:

Download English Version:

<https://daneshyari.com/en/article/8437262>

Download Persian Version:

<https://daneshyari.com/article/8437262>

[Daneshyari.com](https://daneshyari.com)